Company Overview and News
Forced by minority shareholders to reconsider the re-appointment of Neeraj Kanwar as managing director, Apollo Tyres said on Wednesday the board would back the re-appointment while seeking an independent assessment on the compensation. Minority shareholders had defeated a special resolution to extend Kanwar’s tenure beyond 2019, ostensibly unhappy with the very high compensation package, estimated by proxy advisory firm IIAS at around Rs 65 crore.
GOODYEAR 500877 500168 APOLLOTYRE AYRQY
Tyre maker Goodyear India is evaluating to enter various segments, including commercial vehicles tyres, as part of plans to expand operations in the country, a top company official said today.
Market Update: The market held on to morning gains, with the Sensex rising around 150 points while the Nifty Midcap index extended rally, rising nearly 1.5 percent.
519588 PWQFY PANAMAPET 500325 BHUSANSTL UBL 532439 TCHQY ASIANPAINT 532321 PIDILITIND PDLTY 500850 BJJQY MS 500570 524820 500055 500331 JMFINANCIL SNDMY RLNIY GE 534690 515030 532827 UNITDSPR 531978 JETAIRWAYS 532945 YYBKY 530005 532432 BAJAJFINSV VED 500180 COALINDIA GOLDINFRA 500820 GOODYEAR IDBI PNCINFRA 514034 532899 532810 TTNQY 533477 532540 ZUARIGLOB 512529 RIGD INFRATEL INDHOTEL TATAMOTORS 500034 514043 SUNDARMFIN INDUSINDBK UBHOLDINGS 513599 532527 532648 UNBWY VTUWY CDLYY OBEROIRLTY HDB 500168 GNE KARURVYSYA EXCELINDUS TTM 523405 RICOAUTO 539150 PAGEIND 590003 HIMATSEIDE RKFORGE 532755 532478 532511 CADILAHC 532482 534816 JBFIND KSCL 500378 500252 CLNDY 500650 PGDQY ENKEIWHEL 520008 AMBIKCO 539302 LAXMIMACH TECHM BAJFINANCE TATASTEEL TATLY JINDALSAW UQNTY TCS 534809 PCJEWELLER 507458 500780 WABAG HINDCOPPER SHRIRAMEPC BHRYY MONTECARLO RELIANCE ASAHIINDIA 532617 533273 532978 533278 538836 GRANULES 500470 532187 HDFCBANK SEQUENT INDIACEM 590071 YESBANK GEC 500116 533269 POWERMECH PFC DFM OBZIY TTST LAKSHVILAS EXCELCROP
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to NSE:GOODYEAR / GOODYEAR INDIA LTD. on message board site Silicon Investor.